Article
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Nov 2008
Spearman Andrew D, Sweet Kevin, Zhou Xiao-Ping, McLennan Jane, Couch Fergus J, Toland Amanda Ewart
Abstract excerpt
PURPOSE: Twenty percent of individuals with a strong family and/or personal history of breast and ovarian cancer carry a deleterious mutation in BRCA1 or BRCA2. Identification of mutations in these genes is extremely beneficial for patients pursuing risk reduction strategies. Approximately 7% of individuals who have genetic testing of BRCA1 and BRCA2 carry a variant of uncertain significance (VUS), making...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
